The introduction of new antipsychotics has resulted in the availability of drugs with improved safety and tolerability as well as proven efficacy compared to the older antipsychotics. New compounds might show new or different adverse effects that arise in the post-marketing phase when a greater number of patients are treated. One goal of the drug safety program in psychiatry AMSP (Arzneimittelsicherheit in der Psychiatrie) is the detection and description of severe, new, or rare adverse drug reactions (ADRs). Between 1993 and 2000, 122,562 patients were monitored in 35 psychiatric institutions, 86,349 patients of which received antipsychotics. Hyperglycemia related to antipsychotics was observed in association with only two compounds so far: clozapine and olanzapine (clozapine 2 cases, olanzapine 7 cases). In 6 of 9 patients, weight gain preceded hyperglycemia. The relative frequency of these adverse drug related events was 0.013 % for clozapine and 0.075 % for olanzapine. The symptomatology included reversible hyperglycemia, worsening of existing diabetes, and new-onset diabetes. Control for glycemic dysregulation should be maintained in clinical practice with these drugs.
References
1 Arzneimittelkommission der Deutschen Ärzteschaft: Olanzapin: hyperosmolares Coma diabeticum, Rhabdomyolyse, Nieren-insuffizienz. Deutsches Ärzteblatt 2002 11: A742-743
2
Baptista T, Lacruz A, de Mendoza S, Mendoza Guillen J M, Silvera R, Angeles F ,. et al .
Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones.
Pharmacopsychiatry.
2000;
33
81-88
3
Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza M T,. et al .
Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration.
Pharmacopsychiatry.
2001;
34
223-231
4
Baptista T, Kin N M, Beaulieu S, De Baptista E A.
Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Pharmacopsychiatry.
2002;
35
205-219
5
Baymiller S P, Ball P, McMahon R P, Buchanan R W.
Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment.
Schizophr Res.
2003;
59
49-57
9
Fulton B, Goa K L.
Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychotic disorders.
Drugs.
1997;
53
281-298
10
Goldstein L E, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey G K,. et al .
New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment.
Psychosomatics.
1999;
40
438-443
11
Grohmann R, Rüther E, Engel R R, Hippius H.
assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI.
Pharmacopsychiatry.
1999;
32
21-28
12
Grohmann R, Hippius H, Müller-Oerlinghausen B, Rüther E, Scherer J, Schmidt L G,. et al .
Assesment of adverse drug reactions in psychiatric hospitals.
Eur J Clin Pharmacol.
1984;
26
727-734
13
Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R.
Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.
J Clin Psychiatry.
1998;
59
294-299
14
Henderson D C, Cagliero E, Gray C, Nasrallah R A, Hayden D L, Schoenfeld D A,. et al .
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study.
Am J Psychiatry.
2000;
157
975-981
15
Kamran A, Doraiswamy P M, Jane J L, Hammett E B, Dunn L.
Severe hyperglycemia associated with high doses of clozapine.
Am J Psychiatry.
1994;
151
1395
18
Koro C E, Fedder D O, L’Italien G J, Weiss S S, Magder L S, Kreyenbuhl J.
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.
Br Med J.
2002;
325
243-247
20
Lindenmayer J P, Smith R C, Singh A, Parker B, Chou E, Kotsaftis A.
Hyperglycemia in patients with schizophrenia who are treated with olanzapine.
J Clin Psychopharmacol.
2001;
21
351-353
21
Melkersson K I, Hulting A L, Brismar K E.
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.
J Clin Psychiatry.
2000;
61
742-749
28
Sernyak M J, Leslie D L, Alarcon R D, Losonczy M F, Rosenheck R.
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Am J Psychiatry.
2002;
159
561-566
29
Sowell M O, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg H O, Breier A ,. et al .
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.
J Clin Endocrinol Metab.
2002;
87
2918-2923
